We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Sandbox Reserved 1165

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
Secretin-like receptors are composed entirely of alpha helices in their 7TM and ECD. A distinct feature of class B receptors is the N-terminal end of helix one in the 7TM. It extends an extra three helical turns into the ECD, and is longer than any of the class A receptors. This region, referred to as the "stalk" of class B receptors, is highly involved in glucagon binding and also helps in defining the orientation of the ECD with respect to the 7TM domain <ref name="Structure">PMID: 26227798</ref>.
Secretin-like receptors are composed entirely of alpha helices in their 7TM and ECD. A distinct feature of class B receptors is the N-terminal end of helix one in the 7TM. It extends an extra three helical turns into the ECD, and is longer than any of the class A receptors. This region, referred to as the "stalk" of class B receptors, is highly involved in glucagon binding and also helps in defining the orientation of the ECD with respect to the 7TM domain <ref name="Structure">PMID: 26227798</ref>.
-
==Extracellular Tips==
+
==Class A vs. Class B GPCRs==
-
The locations of the extracellular tips for class B glucagon receptors allow for a much wider and deeper binding cavity in the ligand-binding pocket, which is much more immense than any of the class A GCGRs <ref name="Tips">PMID: 23863937</ref>. These wide ranges specifically occur between alpha helices two and six (green) and three and seven (red).
+
Comparison of the 7TM of class B GCGRs was compared to that of class A, and it was found that the orientation and positioning of the helices are conserved through both classes. But, structural alignments of the two revealed multiple gaps in the transmembrane region signifying a variety of structural deviations in transmembrane helices <ref name="Tips">PMID: 23863937</ref>. The N-terminal end of helix one in class B GCGR, located in the 7TM, is longer than any known class A GPCR structures and stretches three supplementary helical turns above the extracellular (EC) membrane boundary. This region is referred to as the stalk and is involved in glucagon binding and also helps in defining the orientation of the ECD with respect to the 7TM domain <ref name="Tips">PMID: 23863937</ref>. Also specific to class B GPCRs, a glycine residue at position 393 induces a bend in helix VII; the bend is stabilized by the hydrophobic interaction between the glycine 393 and phenylalanine 184. One of the most distinguishable characteristics of class B is the helix VIII tilt of 25 degrees compared to that of class A. This results from a Glu 406 in helix VIII that is fully conserved in secretin-like receptors and forms two interhelical salt bridges with conserved residues Arg 173 and Arg 346 <ref name="Tips">PMID: 23863937</ref>. Despite these differences, a vital region that is conserved in both class B and class A receptors is the disulphide bond between Cys 294 and Cys 224 in ECL2. This bond stabilizes the receptors entire 7TM fold. The locations of the extracellular tips for class B glucagon receptors allow for a much wider and deeper binding cavity in the ligand-binding pocket, which is much more immense than any of the class A GCGRs <ref name="Tips">PMID: 23863937</ref>. These wide ranges specifically occur between alpha helices two and six (green) and three and seven (red).

Revision as of 20:07, 22 March 2016

[[Image:]]

This Sandbox is Reserved from Jan 11 through August 12, 2016 for use in the course CH462 Central Metabolism taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1160 through Sandbox Reserved 1184.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Human Glucagon Class B G Protein-Coupled Receptors (GPCRs)

Class B 7TM

Drag the structure with the mouse to rotate

Clinical Relevancy

Of the fifteen human class B GPCRs, eight have been identified as potential drug target[6]. Therapeutic agents have been created from the peptides themselves within this protein, but overall pharmaceutical companies have had difficulty creating agents that act on family B GPCRS. There is an outward appearance and inherent flexibility in the class B GCGR 7TM because of conserved hydrogen bonds that flank a glycine residue, and this structure along with the ECD and its role of interactions on the extracellular side of receptors may provide evidence to how class B receptors adjust its conformational spectra for various receptors. Researchers hope to show how these conformations can be utilized in potential treatments of a wide array disorders. Research for class B GCGR inhibitors is primarily looking into allosteric inhibitors having the ability to target specific receptors in order to treat things like stress disorders, managing excess glucose in the bloodstream, and also alternative mechanisms for treating migraines [7]. Known inhibitors include monoclonal antibodies which inhibit GCGR through an allosteric mechanism. The monoclonal antibodies bind to two different sites, the ECD opposite of the binding region and then the helical portion of the ECD as well. But, these antibodies did not interact with the binding sites. This inhibitor shows further prove of importance that the ECD is to the function of GCGR [8].

References

  1. 1.0 1.1 Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends Pharmacol Sci. 2014 Jan;35(1):12-22. doi: 10.1016/j.tips.2013.11.001. Epub, 2013 Dec 18. PMID:24359917 doi:http://dx.doi.org/10.1016/j.tips.2013.11.001
  2. Yang L, Yang D, de Graaf C, Moeller A, West GM, Dharmarajan V, Wang C, Siu FY, Song G, Reedtz-Runge S, Pascal BD, Wu B, Potter CS, Zhou H, Griffin PR, Carragher B, Yang H, Wang MW, Stevens RC, Jiang H. Conformational states of the full-length glucagon receptor. Nat Commun. 2015 Jul 31;6:7859. doi: 10.1038/ncomms8859. PMID:26227798 doi:http://dx.doi.org/10.1038/ncomms8859
  3. 3.0 3.1 3.2 3.3 3.4 3.5 Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013 Jul 25;499(7459):444-9. doi: 10.1038/nature12393. Epub 2013 Jul 17. PMID:23863937 doi:10.1038/nature12393
  4. 4.0 4.1 Miller LJ, Dong M, Harikumar KG. Ligand binding and activation of the secretin receptor, a prototypic family B G protein-coupled receptor. Br J Pharmacol. 2012 May;166(1):18-26. doi: 10.1111/j.1476-5381.2011.01463.x. PMID:21542831 doi:http://dx.doi.org/10.1111/j.1476-5381.2011.01463.x
  5. Thomsen J, Kristiansen K, Brunfeldt K, Sundby F. The amino acid sequence of human glucagon. FEBS Lett. 1972 Apr 1;21(3):315-319. PMID:11946536
  6. Bortolato A, Dore AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of Class B GPCRs: new horizons for drug discovery. Br J Pharmacol. 2014 Jul;171(13):3132-45. doi: 10.1111/bph.12689. PMID:24628305 doi:http://dx.doi.org/10.1111/bph.12689
  7. Mukund S, Shang Y, Clarke HJ, Madjidi A, Corn JE, Kates L, Kolumam G, Chiang V, Luis E, Murray J, Zhang Y, Hotzel I, Koth CM, Allan BB. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J Biol Chem. 2013 Nov 4. PMID:24189067 doi:http://dx.doi.org/10.1074/jbc.M113.496984
  8. Hoare SR. Allosteric modulators of class B G-protein-coupled receptors. Curr Neuropharmacol. 2007 Sep;5(3):168-79. doi: 10.2174/157015907781695928. PMID:19305799 doi:http://dx.doi.org/10.2174/157015907781695928
Personal tools